The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IWWM-11 2022 | Changes in gene expression in patients with WM after treatment with BTK inhibitors
Amy Christian, BSc, MSc, University Hospitals Dorset NHS Foundation Trust, Dorset, UK, discusses the results from a pilot study which used next-generation sequencing (NGS) techniques to evaluate changes in gene expression in patients with Waldenström’s macroglobulinemia (WM) before and after treatment with a Bruton’s tyrosine kinase (BTK) inhibitor. Ms Christian notes the upregulation of NCR1 and downregulation of CXCL13 observed in patients treated with acalabrutinib. This interview took place at the 11th International Workshop on Waldenström’s Macroglobulinemia (IWWM-11), held in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
